<![CDATA[Novel Agent Begins STARLIGHT-1 Dose Expansion in Relapsed/Refractory B-Cell NHL]]>

Phase 2positivePositive

AI Analysis

Summary

A novel agent is advancing to dose expansion in the STARLIGHT-1 trial for relapsed/refractory B-cell NHL, with all complete responses sustained through 6 months in evaluable patients without CNS involvement from the dose-escalation cohort.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

All complete responses sustained through 6 months in evaluable patients with B-cell NHL without CNS involvement during dose-escalation portion

Importance:6/10

Sentiment:

0.70

oncologylymphomaPhase 2dose expansioncomplete response

Read the original article

Published by Cancer Network on July 24, 2026 3:00 PM

Read Original